Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.

Foster WS. et al, (2022), Cell Rep Med

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.

Padron-Regalado E. et al, (2022), Sci Rep, 12

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.

van Doremalen N. et al, (2022), Nat Commun, 13

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.

Rosadas C. et al, (2022), J Virol Methods, 302

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.

Spencer AJ. et al, (2022), EBioMedicine, 77

Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced protection from malaria

EWER K., (2022), Frontiers in Immunology

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

EWER K. et al, (2021), The Lancet

Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice.

Collins KA. et al, (2021), Sci Rep, 11

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Barrett JR. et al, (2021), Nature medicine

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nature medicine

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial.

LAMBE T. et al, (2020), Nature Medicine

Antigen-specific competitive inhibition of CD4+ T cell recruitment into the primary immune response

Spencer AJ. et al, (2020)

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.

van Doremalen N. et al, (2020), bioRxiv : the preprint server for biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2020), Nat Med

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2020), Lancet

Abstracts from the 3rd Annual Infection and Immunity Meeting: A meeting of the BSI Infection & Immunity Affinity Group Held on Thursday 11 April 2013 at Park Crescent Conference Centre, 229 Great Portland Street, London W1W 5PN

(2013), Clinical and Experimental Immunology, 173, 1 - 4

Include forthcoming?